SG Americas Securities
SPRO icon

SG Americas Securities’s Spero Therapeutics SPRO Stock Holding History

SG Americas Securities’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Buy
+11,268
New +$29.5K ﹤0.01% 3255
2021
Q4 		– Sell
-10,617
Closed -$195K – 3775
2021
Q3 		$195K Buy
+10,617
New +$170K ﹤0.01% 3251
2020
Q3 		– Sell
-7,858
Closed -$106K – 3393
2020
Q2 		$106K Buy
+7,858
New +$88.2K ﹤0.01% 3336

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities's SPRO Position: Q2 2026 in Review

SG Americas Securities opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 11,268 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #3255 among its holdings. This is a return to the name: SG Americas Securities previously reported a position in SPRO as recently as Q3 2021.

SG Americas Securities first reported a position in SPRO in Q2 2020 and has held it in 3 quarters since. The position peaked at $195K in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • SG Americas Securities held 11,268 shares of Spero Therapeutics worth $25K as of Q2 2026.
  • Spero Therapeutics was a new SG Americas Securities position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3255 holding.
  • SG Americas Securities first reported a position in Spero Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • SG Americas Securities's Spero Therapeutics position peaked at $195K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.